Bioasis Technologies (BTI.V) hired Shadow Lake Group, and affiliate, SLG Europe BV, as a business development adviser earlier this week, according to a press release.
This one’s a no-brainer.
It’s the logic behind outsourcing at work. The folks at Bioasis should be left to focus on their proficiency—which is putting together the product, doing the science, and getting it right—and thereby leaving the commercialization and business development to a group like SLG, which excels there.
“The team at SLG is very excited to be working with Bioasis once again to support commercialization of this important and much-needed BBB [blood-brain barrier] delivery platform. We are impressed with the significant progress that the Bioasis team has made in both scientific and business development activities since our previous engagement, and we are looking forward to contributing to the future growth of the company,” said John Proffett, managing partner and co-founder of SLG.
Bioasis Technologies is a biopharma company developing a technology that delivers drugs and other therapeutics past the blood brain barrier to treat certain central nervous system disorders where there’s a high unmet medical need, including cancers and neurodegenerative diseases. Bypassing the blood-brain barrier is a big deal for the treatment of neurological diseases.
Their xB3 platform, once upon known called the transcend-peptide, is based on a human transport protein already found in low doses in the blood. It’s shown to be useful in developing molecules across the blood-brain barrier to reach its targets in the brain through a process called receptor-mediated transcytosis.
This process happens when molecules attach to receptors on the cell surface of endothelial cells forming the blood brain barrier. The receptors tug the molecules through the cells, and get access to the brain. Preclinicals have proven that the platform can transport molecules of various sizes and shapes including monoclonal antibodies, enzymes, small molecules and small-interfering RNA (siRNA) and other gene therapies into the brain.
“We are delighted to engage with Shadow Lake Group to expand our business development efforts. The team at SLG will be able to leverage their previous knowledge of the xB3 platform as well as their extensive transaction experience in neuroscience and oncology in the establishment of new and meaningful strategic partnerships for Bioasis,” said Dr. Deborah Rathjen, PhD, Bioasis’s executive chair.
BTI is up 7.7% today and closed at $0.28.
—Joseph Morton
Full disclosure: Bioasis Technologies is an equity.guru marketing client.
